1. Introduction {#sec1-cells-08-01493}
===============

Rheumatoid arthritis (RA) is one of the most common inflammatory arthritis affecting 0.5--1.0% of the population \[[@B1-cells-08-01493]\]. RA is a systemic autoimmune disease characterized by inflammation of the synovial membrane and periarticular structures. Joint pain, stiffness, and swelling are the primary symptoms, which eventually lead to joint deformity and functional disability. Extra-articular manifestations, including cardiovascular, pulmonary, psychological and skeletal disorders are common in RA patients \[[@B2-cells-08-01493]\]. The etiology and pathophysiology of RA remain unresolved; however, genetic and environmental factors have been associated with the inappropriate immunomodulation that triggers the inflammatory process in the joints and the subsequent damage to synovial structures \[[@B3-cells-08-01493]\]. The treatment of RA aims to reduce pain and inflammation in the joints and also to preserve their structural integrity and the patient's functionality. Currently, treatment includes a variety of pharmacological agents, education programs, joint protection, lifestyle changes, PE and surgical intervention as a final step \[[@B4-cells-08-01493],[@B5-cells-08-01493],[@B6-cells-08-01493]\].

PE is considered in the multidisciplinary management of RA patients. The European League Against Rheumatism (EULAR) has established the recommendations for physical activity in people with inflammatory arthritis \[[@B4-cells-08-01493]\], and its recommendations for cardiovascular disease risk management in RA include regular exercise \[[@B7-cells-08-01493]\]. It has been previously shown that PE improves joint health \[[@B8-cells-08-01493]\], muscle strength \[[@B9-cells-08-01493]\], cardiovascular fitness \[[@B10-cells-08-01493]\], vascular function \[[@B11-cells-08-01493]\], and psychological well being \[[@B12-cells-08-01493]\]. PE also reduces the inflammation \[[@B13-cells-08-01493]\], rheumatoid cachexia \[[@B14-cells-08-01493]\], and fatigue \[[@B15-cells-08-01493]\] in RA patients.

Although the systemic benefits of PE in rheumatic patients are well recognized, the direct consequences of PE in active synovitis and the potential role of PE accelerating joint destruction are not clear. Some reports have shown that mechanical load influences the onset and worsens the progression of the disease in experimental animal models of arthritis \[[@B16-cells-08-01493],[@B17-cells-08-01493]\]; therefore, the consequences of PE on inflamed joints remain a topic that should be addressed.

We selected adjuvant-induced arthritis (AIA) because it mimics the signs and symptoms of human RA, such as the histopathological changes of inflammation, vascular proliferation, and importantly, the progression to joint destruction \[[@B18-cells-08-01493]\]. The AIA model has been widely used in the development of antirheumatic drugs, including several non-steroid anti-inflammatories, methotrexate \[[@B19-cells-08-01493]\], and also biologic drugs, including tocilizumab \[[@B20-cells-08-01493]\] and Jak-inhibitors like tofacitinib \[[@B21-cells-08-01493]\].

To understand the effects of PE in the complexity of the inflamed joint, we selected an unbiased approach to maintain a broad perspective. We selected the bioinformatic analysis of the transcriptome from the tarsal joint through a DNA microarray. The microarray simultaneously evaluates the expression levels for a large number of genes \[[@B22-cells-08-01493]\]; and, identifies the most relevant mediators in complex processes such as the interplay between PE and inflammation.

A better understanding of the molecular consequences of PE on the inflamed joints may contribute to improving its prescription for RA patients for the protection of joint integrity. In this regard, the objective of this study was to determine the effect of an exercise intervention on the transcriptional expression of genes in the AIA rat model using microarray technology.

2. Materials and Methods {#sec2-cells-08-01493}
========================

2.1. Animals and Study Groups {#sec2dot1-cells-08-01493}
-----------------------------

Male Wistar rats (300--350g) were used for this study. The animals were housed in an animal facility with a 12 h light/dark cycle maintained at temperatures between 22 ± 1 °C with food and water provided at libitum. The experimental protocol was approved by the Committee of Ethics of the Instituto Chihuahuense de Salud-Secretaría de Salud-Facultad de Medicina y Ciencias Biomédicas, UACH (protocol number CEI-EXP-140/15). The animals were randomly divided into two groups of seven animals each: (1) arthritis group and (2) arthritis-exercise group.

2.2. Arthritis Induction {#sec2dot2-cells-08-01493}
------------------------

The AIA model was conducted as previously reported \[[@B23-cells-08-01493]\]. Rats were injected in the footpads with 0.2 mL of Complete Freund's Adjuvant (CFA) (Sigma Chemicals, St. Louis, MO, USA) mixed with phosphate buffer saline in the 1:1 ratio. To increase the severity of arthritis, a booster injection with 0.1 mL of the emulsion was administered in the same way on day 5--post first injection.

2.3. Familiarization {#sec2dot3-cells-08-01493}
--------------------

Animals belonging to the arthritis-exercise group were familiarized with the treadmill for three weeks to reduce their stress level during the PE. Each daily familiarization session included placing the rats on the treadmill switched off for 10 min (visual/olfactory adaptation) and then turning on the treadmill at the minimum speed (3 m/min) for 5 min (sound/movement adaptation). After the first week of the treadmill familiarization, arthritis induction was started and the familiarization period continued for two more weeks.

2.4. Physical Capacity Test {#sec2dot4-cells-08-01493}
---------------------------

After the familiarization, a physical capacity test (PCT) was conducted to establish the maximum speed reached by the animals before the intervention of PE. The PCT consisted of a single treadmill session in which the rats, after 5 min of warm-up (3 m/min), ran in the band with an increase in the speed of 3 m/min every 2 min until they fatigued and stopped running. The maximal physical capacity (100%) was defined as the maximum speed reached by each animal. The average speed per group was calculated, and this was used to establish the speed of the exercise sessions.

2.5. Exercise Program {#sec2dot5-cells-08-01493}
---------------------

The rats were exercised three times a week for eight weeks. The exercise started with a speed of 20% of the PCT and increases of 13% in speed were applied every two weeks until reaching 60%. Each exercise session included four phases: (1) acclimatization: rats were placed on the treadmill switched off for 5 min; (2) warm-up: rats walked for 5 min at lowest speed; (3) exercise: rats run for 25 min at the corresponding speed; and (4) cool down: rats walked at lowest speed for 5 min. The exercise sessions were administered at the same time each day.

2.6. Histological Analysis {#sec2dot6-cells-08-01493}
--------------------------

After exercise intervention, the rats were euthanized, and the tarsal joints were immediately dissected. The ankle, the subtalar and the navicular cuboid joints were extracted and cut proximally in the distal fibula and tibia; and, distally in the metatarsal bones at the diaphysis. The muscle was dissected as much as possible and the synovial and ligament structures were preserved and fixed in 10% formalin phosphate buffer for 48 h and decalcified with 5% nitric acid for 24 h \[[@B24-cells-08-01493]\]. The tissues were dehydrated in graded ethanol, and embedded in paraffin, sectioned, and stained with hematoxylin-eosin (H&E Merck, Darmstadt, Germany). The histological variables: (a) inflammatory infiltrate, (b) synovial hyperplasia, (c) pannus formation, (d) synovial vascularity, (e) cartilage damage and (f) bone erotion were semi-quantitatively evaluated using a scale of 0 = absent, 1 = mild, 2 = moderate and, 3 = severe on each animal. The maximum score reached per animal for each parameter was 12 when the four joints showed a severe level. The scoring average per study group was estimated. The histological variables were evaluated bu two experienced operators blinded to the different groups.

2.7. DNA Microarray and Bioinformatics Analysis {#sec2dot7-cells-08-01493}
-----------------------------------------------

The effect of PE on transcriptome was evaluated in the DNA microarray by comparing the arthritis-exercise group (experimental group) and the arthritis group (reference group). The tarsal joints dissected were immediately placed in liquid nitrogen and disrupted with mortar and pestle. Total RNA was extracted using RNeasy^®^ Lipid Tissue Mini Kit (QIAGEN, Germantown, MD, USA) according to the manufacturer´s instructions. The RNA quality and integrity were verified using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). For the microarray, the RNA of every group was pooled keeping equimolar quantities of every individual.

The microarray analysis was performed at the Institute of Cellular Physiology of the National Autonomous University of Mexico (México City, México). Briefly, the cDNA was synthesized and labeled for subsequent hybridization in the Rn5K microchip containing 5000 rat genes. Scanning and signal acquisition was performed using the ScanArray 4000 (Packard BioChips Technologies, Billerica, MA, USA). The GenArise software was used for the analysis of the microarray scan, and the lists of DEGs \[Z-score ≥ 1.5 standard deviations (SD)\] were obtained. To assess the biological relevance of the DEGs, DAVID Bioinformatics Resources 6.8 platform (<https://david.ncifcrf.gov/>) was used. Gene Ontology (GO) and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway mapper with significant associations (*p* ≤ 0.5) were obtained \[[@B25-cells-08-01493]\]. Also, the STRING 10.5 database (<http://string-db.org/>) was used to obtain the analysis and integration of direct and indirect protein-protein interactions (IPP) centered on the functional association \[[@B26-cells-08-01493]\]. The DEGs identified in the microarray were loaded, and the interactions were selected with minimal confidence (interaction score \> 0.4). The obtained IPP network was analyzed more thoroughly to obtain primary clusters of sub-networks using the Cytoscape software version 3.7.0 (Bethesda, Rockville, MD, USA) with the Molecular Complex Detection (MCODE) complement \[[@B27-cells-08-01493],[@B28-cells-08-01493]\].

2.8. Statistical Analysis {#sec2dot8-cells-08-01493}
-------------------------

The statistical analysis was made in SPSS statistics v22 software (SPSS Science Inc., Chicago, IL, USA). Measures of central tendency were estimated for each variable. T-test was used to compare the effect of PE on histological parameters. Differences were considered significant when *p* \< 0.05.

3. Results {#sec3-cells-08-01493}
==========

3.1. Maximal Physical Capacity {#sec3dot1-cells-08-01493}
------------------------------

The maximal physical capacity obtained in the PCT for the arthritis-exercise group was 21.28 ± 5.96 m/min. The initial speed and its increments along the exercise intervention were based on this value.

3.2. Histological Analysis {#sec3dot2-cells-08-01493}
--------------------------

The effect of exercise in the joints was histologically evaluated using H&E staining. The scores of inflammatory infiltrate, synovial hyperplasia, pannus formation, synovial vascularity, and cartilage and erosions obtained for each study group are shown in [Figure 1](#cells-08-01493-f001){ref-type="fig"}. The highest scores of all evaluated parameters were reached in the arthritis exercise group. However, only hyperplasia, cartilage damage and bone erosion were statistically different between the groups.

3.3. Microarray and Bioinformatic Analysis {#sec3dot3-cells-08-01493}
------------------------------------------

The transcriptome-wide microarray analysis identified a pool of DEGs in the joints from arthritic exercised rats in comparison to arthritic non-exercised rats. A total of 719 genes were differentially expressed (Z-score ≥ 1.5 SD), 361 up-regulated ([Appendix A](#app1-cells-08-01493){ref-type="app"}), and 358 down-regulated ([Appendix B](#app2-cells-08-01493){ref-type="app"}). AB000928 (Zp1) and X68101 (Trg) were the most significantly up- and down-expressed genes by PE, respectively.

To understand the related biological functions of the 719 DEGs, we used the DAVID database for the enrichment analysis of GO and KEGG pathways. The top 10 enriched terms of GO and KEGG pathways are shown in [Figure 2](#cells-08-01493-f002){ref-type="fig"}. Response to organic cyclic compound, response to drug, and response to ethanol were among the top enriched biological processes. The DEGs were enriched in molecular functions like protein binding. The most enriched KEGG pathways included hypoxia-induced factor-1 (HIF-1), cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) signaling pathways. Subsequently, we selected the biological processes and KEGG signaling pathways known to be relevant in the pathogenesis of RA, which included: response to hypoxia, response to oxidative stress, angiogenesis and inflammatory/immune response ([Table 1](#cells-08-01493-t001){ref-type="table"}).

After the analysis on DAVID, the list of the 719 DEGs was analyzed on the STRING and Cytoscape-MCODE platforms. The first three clusters obtained are shown in [Figure 3](#cells-08-01493-f003){ref-type="fig"}, [Figure 4](#cells-08-01493-f004){ref-type="fig"} and [Figure 5](#cells-08-01493-f005){ref-type="fig"}. The genes from the first three clusters were loaded in STRING to identify the associated KEGG signaling pathways; those relevant in RA were selected and marked with different colors. The pathways considered as relevant included the HIF-1 signaling pathway. The analysis of the protein networks unveiled relevant genes dysregulated by PE. Those presented multiple functional connections included up-regulated genes such as serine-threonine protein kinases Akt1, Akt2, and Akt3; the vascular endothelial growth factor A (Vefga), the mitogen-activated protein kinase kinase 1 (Mapk1), phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform (Pik3cb), glucokinase (Gck), fructose-biphosphatase2 (Fbp2); and also down-regulated genes such as interleukin 6 (Il6).

4. Discussion {#sec4-cells-08-01493}
=============

Current evidence describing the influence of PE on the pathogenic mechanisms of the arthritides is scarce and limited to studies in animal models. Most of these studies have focused on animal models of osteoarthritis and, in most cases, only clinical and histological parameters have been evaluated, limiting our understanding of the PE in the pathogenesis of active synovitis. To our knowledge, no previous study has assessed the effects of PE on the transcriptome profile in the AIA model.

Our study shows that PE induced several genes linked to RA pathogenesis. Specifically, PE exacerbated hypoxia, oxidative stress, and the immune/inflammatory response in rats with AIA. The histology confirms our transcriptome results; in the joints of the exercised animals, we observed an increase in the inflammatory infiltrate and more severe scores for bone and cartilage destruction.

In our opinion, the connection between PE and its potential detrimental role at active stages of synovitis should be considered as a relevant event in patients with inflammatory arthritides. Current recommendations for physical activity and PE in people with inflammatory and non-inflammatory arthritis \[[@B4-cells-08-01493],[@B5-cells-08-01493],[@B7-cells-08-01493],[@B29-cells-08-01493]\] have been established mostly on clinical studies in humans, which the intimate effect of PE in the arthritic joints at a molecular level has not been considered. These recommendations have not been specified according to the disease activity; however, as our study shows, likely at very active stages of inflammatory arthritides, PE could increase the inflammatory process. It is unlikely that PE will be prescribed in patients with active arthritis; however, a wide prescription of PE could also include the large proportion of patients whom remain with some degree of inflammatory activity despite therapy. Probably, the PE benefits may not be as clear in those patients with partial disease control. Therefore, the disease activity should be considered as an element for PE prescription.

RA pathogenesis remains a primary research field; we now understand that the rheumatoid pannus is an altered microenvironment that carries a significant array of abnormal immune processes and also several metabolic alterations. The increase in hypoxia and oxidative stress are recognized as relevant inflammation drivers within the rheumatic synovium. Their pathological implications are now sustained by experimental results both: in animal models \[[@B30-cells-08-01493],[@B31-cells-08-01493]\] and human disease \[[@B32-cells-08-01493],[@B33-cells-08-01493]\]. Synovial hypoxia promotes inflammation, angiogenesis, production of chemokines, and cartilage and bone destruction, mediated in part, through HIF-1 that is a potent pleiotropic mediator \[[@B32-cells-08-01493],[@B34-cells-08-01493]\].

Our study confirms that PE up-regulates genes linked to hypoxia and oxidative stress in the arthritic joints; indeed, the HIF-1 signaling was the first enriched pathway in our bioinformatic analysis, suggesting that this pathway was the strongest influenced by the PE. Downstream HIF-linked genes as the vascular endothelial growth factor (VEGF) are also up-regulated. VEGF is critical for the onset and perpetuation of vascular proliferation in synovitis \[[@B35-cells-08-01493],[@B36-cells-08-01493],[@B37-cells-08-01493]\]. Also, it was previously reported the VEGF increase in the serum and synovial fluid of RA patients \[[@B35-cells-08-01493],[@B38-cells-08-01493]\] as well as in experimental animal models \[[@B39-cells-08-01493]\].

Hypoxia could activate the genes encoding nearly every step of glycolysis \[[@B32-cells-08-01493]\]. Abnormal glucose metabolism was observed in the synovial fluid and synovium of RA, which is evidenced by increased glycolytic enzyme activity \[[@B40-cells-08-01493]\]. A recent study proposes the inhibition of hexokinases as a potential therapeutic strategy in the treatment of patients with RA \[[@B41-cells-08-01493]\]. According to this, the glucokinase (Gck) and the hexokinase 1 (Hk1) were up-regulated by PE in our study. Additionally, genes involved in the oxidative stress process were also dysregulated by PE. It is recognized that in an inflamed joint, hypoxia and reperfusion cycles occur, producing an excessive amount of reactive oxygen species (ROS) known as oxidative stress \[[@B33-cells-08-01493],[@B42-cells-08-01493]\].

In addition to hypoxia and oxidative stress conditions induced by the effect of PE, other KEGG pathways were dysregulated ([Table 1](#cells-08-01493-t001){ref-type="table"}) such as rheumatoid arthritis, T-cell and B-cell receptor signaling, chemokine, Jak-Stat, TNF, Toll-like-receptor, WNT and osteoclast differentiation signaling pathways. This array of dysregulated pathways suggests a widespread effect of PE both in the adaptive and innate immune response.

Other genes participating in several KEGG pathways in our study include Akt1, Akt2, Akt3, Map2k1 and PIk3cb which belong to PI3K/AKT/mTOR and MAPK pathways that are considered central in RA pathogenesis \[[@B43-cells-08-01493],[@B44-cells-08-01493]\]. They have been implicated in fibroblast-like synoviocyte proliferation and activation. They stimulate the production of pro-inflammatory and osteoclastogenic cytokines; besides, the inhibition of either pathway has been correlated with the improvement of disease activity parameters. Therefore, the use of agents with the potential to regulate either PI3K/AKT/mTOR or MAPK pathways has been considered as a potential therapeutic strategy \[[@B45-cells-08-01493]\].

The molecular results of the PE effect are not easily comparable with previous studies due to the low number of reports, which had objectives aimed at particular aspects of the disease. However, we can distinguish that the negative effect of PE has also been reported in the two most recent and complete studies in this field \[[@B16-cells-08-01493],[@B17-cells-08-01493]\]. The results of these studies suggest a direct link between the degree of mechanical stress to inflammation and tissue localization, which strengthens previous studies that propose biomechanical factors as potential determinants for the topographic pattern of joint disorders in arthritis \[[@B46-cells-08-01493]\]. Cambré et al., suggest that the link between mechanical stress and the onset of arthritis is explained by local recruitment of Ly6high inflammatory cells elicited by mechanostress-induced chemokine induction in resident mesenchyme cells \[[@B17-cells-08-01493]\]. They also provide evidence of the local participation of the complement activators to maintain the progression and chronicity of arthritis through an impaired resolution \[[@B16-cells-08-01493]\].

On the other hand, it has been shown that in healthy rats, PE has a positive effect in the joints it induces extracellular matrix biosynthesis, cartilage strengthening, and attenuation of inflammatory pathways \[[@B47-cells-08-01493]\]. This suggests that the gene induction pattern of mechanosensitive genes seems to be distinct between different arthritis models and healthy animals, and likely also in regarding to the degree of arthritis activity.

Consistent with the genetic analysis, our histological findings showed that PE had an adverse effect on increasing the inflammatory infiltrate and the joint destruction. In experimental models of arthritis, it has been confirmed that mechanical stress increase joint inflammation, stimulate the progression and chronicity of arthritis and structural damage \[[@B16-cells-08-01493],[@B17-cells-08-01493],[@B48-cells-08-01493]\]; besides, the mechanical stress decrease the bone quality \[[@B16-cells-08-01493]\]. In contrast to our findings, other studies in the AIA model have shown an anti-inflammatory effect of PE in some parameters such as synovial hyperplasia \[[@B49-cells-08-01493],[@B50-cells-08-01493]\], and joint destruction \[[@B51-cells-08-01493]\].

Mode, intensity, frequency, timing, and duration of the PE protocol are decisive aspects to the physiological responses and different outcomes \[[@B52-cells-08-01493]\]. Moreover, the severity of arthritis at the starting time of PE could be definitory. Studies in the AIA model that started the PE at the pre-arthritic stage \[[@B49-cells-08-01493],[@B50-cells-08-01493]\] showed beneficial results. However, we started the PE at an arthritic stage because we think this scenario is more representative of RA patients.

5. Conclusions {#sec5-cells-08-01493}
==============

The present study explored the influence of PE in the genetic expression and the histology of the actively swollen joints in the AIA model. Our results describe an exploratory and preliminary scenario in which PE increased the expression of genes with a known pathogenic role in RA; these findings were consistent with the histological findings. These results suggest that the PE exacerbated the stressed joint environment, where the inflammation, hypoxia, and the oxidative stress prevail, rendering clear parallels to the RA joints. The molecular effect of exercise on active stages of inflammatory arthropathies requires further studies in animal models and humans, which could contribute with the development of adequate programs for RA patients that can ensure a beneficial effect without negative implications at the tissue level.
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No data

2.224055

BF564018

No data

1.608414

BF565044

No data

1.715644

BF565565

No data

1.534809

BG374035

No data

1.848573

BG664137

No data

1.654493

BG665039

No data

1.996679

BG666176

No data

2.409512

BG668317

No data

1.503399

BG668660

No data

1.902199

BG671436

No data

2.520046

BG671873

No data

2.019116

BG673258

No data

2.563218

BI282584

No data

2.135856

BM383757

No data

1.584869

BQ207374

No data

1.532423

BQ211469

No data

1.62545

BU671396

No data

1.554288

BU671701

No data

2.802387

D00729

enoyl-CoA delta isomerase 1(Eci1)

2.814065

D14480

calpain 8(Capn8)

1.674437

D21095

chemokine (C-X-C motif) ligand 3(Cxcl3)

1.92518

D30040

AKT serine/threonine kinase 1(Akt1)

1.680116

D38261

protein phosphatase 2, regulatory subunit B, gamma(Ppp2r2c)

1.79365

D85435

protein kinase C, delta binding protein(Prkcdbp)

1.78163

D87950

ubiquilin 1(Ubqln1)

1.763773

J00744

No data

1.516659

L04760

tripartite motif-containing 23(Trim23)

2.018875

L07315

dipeptidase 1 (renal)(Dpep1)

1.601127

L13606

myosin heavy chain 2(Myh2)

1.787821

L15618

casein kinase 2 alpha 1(Csnk2a1)

1.7187

L28801

general transcription factor IIIC subunit 1(Gtf3c1)

1.516161

L29427

No data

2.009211

L35921

G protein subunit gamma 8(Gng8)

1.713815

M13011

No data

1.614206

M15883

clathrin, light chain B(Cltb)

1.806758

M21759

filaggrin(Flg)

1.813956

M22030

No data

1.780357

M32062

Fc fragment of IgG, low affinity IIa, receptor(Fcgr2a)

1.60304

M33821

gamma-glutamyltransferase 1(Ggt1)

2.263792

M91450

No data

1.564184

M96626

ATPase plasma membrane Ca

2+

transporting 3(Atp2b3)

2.172804

M97255

trefoil factor 2(Tff2)

1.647276

NM_012519

calcium/calmodulin-dependent protein kinase II delta(Camk2d)

1.505653

NM_012520

catalase(Cat)

2.274713

NM_012526

chromogranin B(Chgb)

2.018038

NM_012528

cholinergic receptor nicotinic beta 1 subunit(Chrnb1)

1.680012

NM_012531

catechol-O-methyltransferase(Comt)

2.231328

NM_012543

D-box binding PAR bZIP transcription factor(Dbp)

1.532421

NM_012549

endothelin 2(Edn2)

1.830311

NM_012565

glucokinase(Gck)

3.003472

NM_012572

glutamate ionotropic receptor kainate type subunit 4(Grik4)

1.960676

NM_012594

lactalbumin, alpha(Lalba)

2.35724

NM_012596

leptin receptor(Lepr)

1.572461

NM_012600

malic enzyme 1(Me1)

1.705429

NM_012612

natriuretic peptide A(Nppa)

1.752513

NM_012619

phenylalanine hydroxylase(Pah)

1.861168

NM_012653

solute carrier family 9 member A2(Slc9a2)

1.680892

NM_012663

vesicle-associated membrane protein 2(Vamp2)

1.751666

NM_012667

tachykinin receptor 1(Tacr1)

2.182398

NM_012695

sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring, member 6(Sult2a6)

1.605457

NM_012730

cytochrome P450, family 2, subfamily d, polypeptide 2(Cyp2d2)

1.829295

NM_012734

hexokinase 1(Hk1)

1.709348

NM_012788

discs large MAGUK scaffold protein 1(Dlg1)

1.700899

NM_012850

growth hormone releasing hormone receptor(Ghrhr)

1.557048

NM_012876

ribosomal protein S29(Rps29)

2.638145

NM_012904

annexin A1(Anxa1)

1.502437

NM_012908

Fas ligand(Faslg)

2.142956

NM_012910

arrestin, beta 1(Arrb1)

1.672619

NM_012941

cytochrome P450, family 51(Cyp51)

1.657199

NM_012963

high mobility group box 1(Hmgb1)

1.666837

NM_012978

luteinizing hormone/choriogonadotropin receptor(Lhcgr)

3.050579

NM_012980

matrix metallopeptidase 11(Mmp11)

2.630092

NM_012993

nardilysin convertase(Nrdc)

2.298098

NM_013005

phosphoinositide-3-kinase regulatory subunit 1(Pik3r1)

2.802073

NM_013008

POU class 1 homeobox 1(Pou1f1)

1.552156

NM_013030

solute carrier family 34 member 1(Slc34a1)

1.569844

NM_013183

meprin A subunit beta(Mep1b)

1.901411

NM_013224

ribosomal protein S26(Rps26)

1.620632

NM_013226

ribosomal protein L32(Rpl32)

2.284438

NM_013413

relaxin 1(Rln1)

1.971464

NM_017015

glucuronidase, beta(Gusb)

1.8737

NM_017042

protein phosphatase 3 catalytic subunit beta(Ppp3cb)

1.989406

NM_017137

chloride channel, voltage-sensitive 2(Clcn2)

1.867684

NM_017144

troponin I3, cardiac type(Tnni3)

1.571609

NM_017169

peroxiredoxin 2(Prdx2)

2.126629

NM_017193

aminoadipate aminotransferase(Aadat)

2.633207

NM_017251

gap junction protein, beta 1(Gjb1)

1.77218

NM_017256

transforming growth factor beta receptor 3(Tgfbr3)

1.864647

NM_017264

proteasome activator subunit 1(Psme1)

1.819425

NM_017279

proteasome subunit alpha 2(Psma2)

1.725385

NM_017348

solute carrier family 6 member 8(Slc6a8)

1.628447

NM_019137

early growth response 4(Egr4)

1.894886

NM_019151

myostatin(Mstn)

2.351448

NM_019161

cadherin 22(Cdh22)

2.206278

NM_019165

interleukin 18(Il18)

1.52836

NM_019170

carbonyl reductase 1(Cbr1)

1.714897

NM_019179

thymidylate synthetase(Tyms)

1.837275

NM_019198

fibroblast growth factor 17(Fgf17)

2.35561

NM_019216

growth differentiation factor 15(Gdf15)

1.772315

NM_019266

sodium voltage-gated channel alpha subunit 8(Scn8a)

2.082371

NM_019272

ssemaphorin 4F(Sema4f)

1.685348

NM_019277

exocyst complex component 6(Exoc6)

1.957294

NM_019291

carbonic anhydrase 2(Car2)

2.185707

NM_019323

mast cell protease 9(Mcpt9)

1.647125

NM_019340

regulator of G-protein signaling 3(Rgs3)

1.639602

NM_019353

thyroid peroxidase(Tpo)

1.757899

NM_019376

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma(Ywhag)

1.753748

NM_019904

galectin 1(Lgals1)

1.747295

NM_020082

ribonuclease A family member 4(Rnase4)

1.5499

NM_021581

prolyl 3-hydroxylase family member 4(P3h4)

1.874377

NM_021585

mast cell immunoglobulin-like receptor 1(Milr1)

1.878356

NM_021598

mast cell protease 8(Mcpt8)

2.72646

NM_021671

transmembrane protein 33(Tmem33)

1.613433

NM_021684

adenylate cyclase 10 (soluble)(Adcy10)

1.83554

NM_021697

potassium voltage-gated channel modifier subfamily V member 1(Kcnv1)

1.756715

NM_021701

protein phosphatase 3, regulatory subunit B, beta(Ppp3r2)

1.764523

NM_021748

N-ethylmaleimide sensitive factor, vesicle fusing ATPase(Nsf)

1.720353

NM_021772

cyclin-dependent kinase-like 3(Cdkl3)

1.589505

NM_021849

RFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase(Rfng)

1.75421

NM_021859

megakaryocyte-associated tyrosine kinase(Matk)

1.846828

NM_021997

CAP-GLY domain containing linker protein 2(Clip2)

1.829356

NM_022203

No data

1.914261

NM_022210

MYC associated factor X(Max)

1.814325

NM_022254

G protein-coupled receptor 85(Gpr85)

1.800299

NM_022282

discs large MAGUK scaffold protein 2(Dlg2)

1.768177

NM_022284

guanylate cyclase activator 2B(Guca2b)

2.039829

NM_022296

xylosyltransferase 2(Xylt2)

2.198775

NM_022297

dimethylarginine dimethylaminohydrolase 1(Ddah1)

1.685947

NM_022509

survival of motor neuron 1, telomeric(Smn1)

1.906114

NM_022538

phospholipid phosphatase 1(Plpp1)

1.909921

NM_022600

adenylate cyclase 5(Adcy5)

1.520435

NM_022613

No data

1.929265

NM_022623

frizzled class receptor 4(Fzd4)

2.230565

NM_022625

tropic 1808(Tpc1808)

1.653187

NM_022638

transient receptor potential cation channel, subfamily C, member 2, pseudogene(Trpc2)

1.663797

NM_022639

cholinergic receptor nicotinic alpha 10 subunit(Chrna10)

1.732239

NM_022686

histone cluster 1, H4b(Hist1h4b)

2.369333

NM_022704

mannose-binding lectin (protein C) 2(Mbl2)

1.568571

NM_022850

dipeptidyl peptidase like 6(Dpp6)

2.262092

NM_022859

cysteine-rich secretory protein 1(Crisp1)

1.609319

NM_022929

potassium voltage-gated channel interacting protein 1(Kcnip1)

1.663328

NM_022947

ClpB homolog, mitochondrial AAA ATPase chaperonin(Clpb)

1.811601

NM_022954

FAT atypical cadherin 2(Fat2)

2.727616

NM_023102

casein kinase 1, gamma 2(Csnk1g2)

1.702925

NM_023963

caudal type homeo box 2(Cdx2)

1.683684

NM_023969

lysophosphatidic acid receptor 3(Lpar3)

1.63442

NM_023973

indoleamine 2,3-dioxygenase 1(Ido1)

1.519611

NM_023981

colony stimulating factor 1(Csf1)

1.538487

NM_023994

taste receptor, type 2, member 118(Tas2r118)

1.695958

NM_023995

taste receptor, type 2, member 107(Tas2r107)

2.24126

NM_024127

growth arrest and DNA-damage-inducible, alpha(Gadd45a)

2.152067

NM_024381

glycerol kinase(Gk)

1.811678

NM_024487

GrpE-like 1, mitochondrial(Grpel1)

1.943116

NM_024489

zinc finger and BTB domain containing 10(Zbtb10)

2.056393

NM_030826

glutathione peroxidase 1(Gpx1)

1.652839

NM_030837

kidney specific organic anion transporter(Slc21a4)

2.998452

NM_030843

syntaxin binding protein 5(Stxbp5)

2.170744

NM_030860

myocyte enhancer factor 2D(Mef2d)

2.048593

NM_030868

nephroblastoma overexpressed(Nov)

1.600397

NM_030875

sodium voltage-gated channel alpha subunit 1(Scn1a)

1.622929

NM_031000

aldo-keto reductase family 1 member A1(Akr1a1)

1.567229

NM_031021

casein kinase 2 beta(Csnk2b)

1.917293

NM_031036

G protein subunit alpha q(Gnaq)

1.918023

NM_031059

msh homeobox 1(Msx1)

1.99165

NM_031065

ribosomal protein L10A(Rpl10a)

2.300643

NM_031085

protein kinase C, eta(Prkch)

2.372214

NM_031093

RAS like proto-oncogene A(Rala)

2.39697

NM_031120

signal sequence receptor, gamma(Ssr3)

1.674383

NM_031129

transcription elongation factor B subunit 2(Tceb2)

2.331149

NM_031130

nuclear receptor subfamily 2, group F, member 1(Nr2f1)

1.84239

NM_031133

thrombopoietin(Thpo)

1.757085

NM_031136

thymosin beta 4, X-linked(Tmsb4x)

2.204979

NM_031142

double C2 domain beta(Doc2b)

2.438734

NM_031240

cysteine-rich secretory protein 2(Crisp2)

2.969829

NM_031352

drebrin-like(Dbnl)

1.689691

NM_031360

sphingomyelin phosphodiesterase 2(Smpd2)

1.509688

NM_031537

RoBo-1(LOC24906)

2.382064

NM_031570

ribosomal protein S7(Rps7)

1.720451

NM_031575

AKT serine/threonine kinase 3(Akt3)

1.827906

NM_031601

calcium voltage-gated channel subunit alpha1 G(Cacna1g)

2.076481

NM_031603

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon(Ywhae)

1.516651

NM_031604

ATPase H+ transporting V0 subunit a1(Atp6v0a1)

2.734505

NM_031621

SH2B adaptor protein 3(Sh2b3)

1.87789

NM_031624

immunoglobulin (CD79A) binding protein 1(Igbp1)

1.647906

NM_031627

nuclear receptor subfamily 1, group H, member 3(Nr1h3)

1.513038

NM_031643

mitogen activated protein kinase kinase 1(Map2k1)

2.033606

NM_031728

synaptosomal-associated protein 91(Snap91)

1.989374

NM_031729

protein phosphatase 5, catalytic subunit(Ppp5c)

1.7209

NM_031762

cyclin-dependent kinase inhibitor 1B(Cdkn1b)

1.807938

NM_031781

amyloid beta precursor protein binding family A member 3(Apba3)

1.770669

NM_031789

nuclear factor, erythroid 2-like 2(Nfe2l2)

2.362231

NM_031821

polo-like kinase 2(Plk2)

2.022837

NM_031823

wolframin ER transmembrane glycoprotein(Wfs1)

2.469074

NM_031832

galectin 3(Lgals3)

1.597594

NM_031836

vascular endothelial growth factor A(Vegfa)

1.578976

NM_031974

clathrin, light chain A(Clta)

1.664435

NM_032079

DnaJ heat shock protein family (Hsp40) member A2(Dnaja2)

1.580883

NM_032082

hydroxyacid oxidase 2(Hao2)

1.813424

NM_033376

potassium two pore domain channel subfamily K member 3(Kcnk3)

1.540317

NM_053323

delta(4)-desaturase, sphingolipid 1(Degs1)

1.581652

NM_053716

fructose-bisphosphatase 2(Fbp2)

1.901898

NM_057098

transcription elongation factor A2(Tcea2)

2.570171

NM_057099

proteasome subunit beta 6(Psmb6)

1.767274

NM_078622

phosphate cytidylyltransferase 1, choline, alpha(Pcyt1a)

1.676003

NM_080900

actin filament associated protein 1(Afap1)

1.565316

NM_130420

tripartite motif-containing 9(Trim9)

2.025582

NM_130421

lymphocyte cytosolic protein 2(Lcp2)

1.912839

NM_130753

fibroblast growth factor 19(Fgf19)

1.524216

NM_133309

calpain 8(Capn8)

2.126877

NM_133321

potassium voltage-gated channel subfamily J member 15(Kcnj15)

2.331074

NM_133383

serine carboxypeptidase 1(Scpep1)

1.565457

NM_133392

serine/threonine kinase 17b(Stk17b)

2.265261

NM_133406

1-acylglycerol-3-phosphate O-acyltransferase 4(Agpat4)

1.599979

NM_133612

No data

1.653442

NM_134376

calsyntenin 3(Clstn3)

1.500037

NM_134462

ATPase secretory pathway Ca2+ transporting 2(Atp2c2)

2.49921

NM_134465

cytokine receptor-like factor 2(Crlf2)

2.519908

NM_138710

DAB2 interacting protein(Dab2ip)

1.61244

NM_139193

prolactin releasing hormone receptor(Prlhr)

1.542231

NM_144741

resistin(Retn)

1.849312

NM_144742

ATPase phospholipid transporting 11A(Atp11a)

2.002968

NM_147207

ischemia related factor vof-16(Vof16)

1.623283

U03390

receptor for activated C kinase 1(Rack1)

1.944424

U05593

Cd80 molecule(Cd80)

2.654472

U06434

C-C motif chemokine ligand 4(Ccl4)

1.819756

U14746

von Hippel-Lindau tumor suppressor(Vhl)

1.543271

U17604

reticulon 1(Rtn1)

1.825625

U18771

RAB26, member RAS oncogene family(Rab26)

1.820437

U39208

cytochrome P450, family 4, subfamily f, polypeptide 6(Cyp4f6)

1.645854

U48828

No data

1.727898

U51583

zinc finger E-box binding homeobox 1(Zeb1)

1.51051

U53475

RAB8B, member RAS oncogene family(Rab8b)

1.913337

U57063

granzyme F(Gzmf)

1.980644

U57391

SH2B adaptor protein 1(Sh2b1)

2.074809

U72353

lamin B1(Lmnb1)

2.074554

U92564

zinc finger protein 423(Zfp423)

2.090788

U93851

cyclic nucleotide gated channel alpha 1(Cnga1)

1.506566

U94856

paraoxonase 1(Pon1)

1.546413

X51992

gamma-aminobutyric acid type A receptor alpha 5 subunit(Gabra5)

1.648049

X52952

Moloney sarcoma oncogene(Mos)

1.892727

X56190

No data

1.501611

X63281

No data

2.264276

X69029

No data

1.553785

X80671

olfactory receptor 1271(Olr1271)

1.74883

X81193

cysteine and glycine rich protein 3(Csrp3)

1.681766

X89603

metallothionein 3(Mt3)

2.362925

X89962

cold shock domain containing C2(Csdc2)

2.244

X96790

glutamate metabotropic receptor 7(Grm7)

1.589366

X98490

replication protein A2(Rpa2)

1.518939

Z75029

heat shock 70kD protein 1B (mapped)(Hspa1b)

1.844737

Gene Id

Gene

Z-Score

AA944170

S/D

−1.506199

AA944489

No data

−1.530233

AA996993

No data

−2.983268

AB011529

cadherin, EGF LAG seven-pass G-type receptor 2(Celsr2)

−1.74635

AB011679

tubulin, beta 5 class I(Tubb5)

−2.325114

AB020504

No data

−2.211124

AB020757

chymotrypsin-like(Ctrl)

−2.059928

AB025017

No data

−2.29894

AB033418

No data

−2.907947

AB047540

isocitrate dehydrogenase 3 (NAD+) beta(Idh3B)

−1.980831

AB067445

integrin alpha 2(Itga2)

−1.977614

AF000944

general transcription factor IIA, 2(Gtf2a2)

−2.614055

AF006664

NK2 homeobox 5(Nkx2-5)

−1.571779

AF012714

multiple inositol-polyphosphate phosphatase 1(Minpp1)

−1.517925

AF015953

aryl hydrocarbon receptor nuclear translocator-like(Arntl)

−1.67005

AF016387

retinoid X receptor gamma(Rxrg)

−1.847981

AF021936

CDC42 binding protein kinase beta(Cdc42bpb)

−2.024961

AF026505

sorbin and SH3 domain containing 2(Sorbs2)

−1.84203

AF032120

GIPC PDZ domain containing family, member 1(Gipc1)

−1.832343

AF037071

nitric oxide synthase 1 adaptor protein(Nos1ap)

−2.242322

AF039584

CD55 molecule, decay accelerating factor for complement(Cd55)

−1.707524

AF053093

No data

−1.976489

AF053097

No data

−1.603483

AF084544

versican(Vcan)

−1.711944

AF092090

polyamine modulated factor 1 binding protein 1(Pmfbp1)

−1.629489

AF123651

spermatogenesis associated 2(Spata2)

−1.791841

AF151710

No data

−1.874231

AF170284

gap junction protein, beta 6(Gjb6)

−2.501274

AF193757

N-terminal EF-hand calcium binding protein 2(Necab2)

−1.515331

AF200359

UDP-glucose glycoprotein glucosyltransferase 1(Uggt1)

−2.250208

AF243515

BCL2/adenovirus E1B interacting protein 3(Bnip3)

−1.627503

AF247450

hyperpolarization-activated cyclic nucleotide-gated potassium channel 1(Hcn1)

−1.51455

AF277901

zinc finger protein 483(Zfp483)

−1.798414

AF302047

CXADR-like membrane protein(Clmp)

−2.140061

AF304429

mitochondrial pyruvate carrier 1(Mpc1)

−2.257792

AF307852

ARP3 actin related protein 3 homolog(Actr3)

−1.95466

AF323615

phospholipase C, epsilon 1(Plce1)

−4.175461

AF329856

phosphodiesterase 1C(Pde1c)

−1.504374

AF347935

interleukin 11(Il11)

−1.674463

AF361476

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2(Cited2)

−1.710103

AF367467

selenoprotein S(Selenos)

−2.382484

AF379608

doublesex and mab-3 related transcription factor 1(Dmrt1)

−1.683129

AF400662

calcium voltage-gated channel auxiliary subunit alpha2delta 1(Cacna2d1)

−1.543195

AF537333

aurora kinase A(Aurka)

−1.661243

AI059699

No data

−1.842174

AI136886

No data

−1.650746

AI229387

No data

−1.511607

AI598392

No data

−1.725522

AJ006855

synaptojanin 1(Synj1)

−1.727807

AJ131196

No data

−1.769069

AJ250280

potassium voltage-gated channel subfamily H member 5(Kcnh5)

−1.520944

AJ303374

ATP binding cassette subfamily G member 1(Abcg1)

−1.609867

AJ409332

TIMP metallopeptidase inhibitor 2(Timp2)

−2.3002

AW141281

No data

−2.051067

AW141994

No data

−1.692865

AW434257

No data

−1.789087

AW915590

No data

−1.557293

AW916146

No data

−1.959788

AW916635

No data

−1.746735

AW917632

No data

−1.549931

AW918748

No data

−2.166549

AW918775

No data

−1.649553

AW919008

No data

−1.692303

AY011335

No data

−1.711045

AY014898

inositol polyphosphate multikinase(Ipmk)

−2.342213

AY026512

dynein light chain roadblock-type 1(Dynlrb1)

−2.119183

BF284301

No data

−2.121369

BF287132

No data

−2.068833

BF392368

No data

−2.212956

BF395339

No data

−1.928218

BF399588

No data

−2.70933

BF414052

No data

−2.155561

BF416262

No data

−1.546722

BF524417

No data

−2.049708

BF549771

No data

−1.690628

BF555199

No data

−1.523037

BF559446

No data

−2.697068

BF560218

No data

−2.252126

BF566173

No data

−2.261156

BF567456

No data

−1.898923

BG663098

No data

−1.5361

BG664103

No data

−2.448298

BG666505

No data

−1.572982

BG667467

No data

−2.508352

BG671325

No data

−1.655659

BI278738

No data

−2.62235

BI295378

No data

−2.278025

BI296499

No data

−2.01441

BM386847

No data

−2.077829

BQ194714

No data

−1.88522

BQ205274

NADH:ubiquinone oxidoreductase subunit A12(Ndufa12)

−2.38962

BQ208291

No data

−1.636124

BU670896

No data

−3.513474

BU671010

No data

−2.556612

BU671095

No data

−2.578096

BU671151

No data

−1.744558

D00920

seminal vesicle secretory protein 3A(Svs3a)

−2.000729

D14048

heterogeneous nuclear ribonucleoprotein U(Hnrnpu)

−2.261341

D16465

adenylate cyclase activating polypeptide 1 receptor type 1(Adcyap1r1)

−1.966142

D16479

hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional protein), beta subunit(Hadhb)

−1.944151

D26178

intestinal cell kinase(Ick)

−2.540983

D63772

solute carrier family 1 member 1(Slc1a1)

−1.665296

J02585

stearoyl-CoA desaturase(Scd)

−2.299181

J02868

cytochrome P450, family 2, subfamily d, polypeptide 3(Cyp2d3)

−1.688779

J04628

3-hydroxyisobutyrate dehydrogenase(Hibadh)

−1.717486

L02121

cyclin-dependent kinase 5(Cdk5)

−2.181096

L02315

calcium voltage-gated channel auxiliary subunit beta 4(Cacnb4)

−1.528497

L10362

synaptic vesicle glycoprotein 2b(Sv2b)

−1.569646

L12407

No data

−1.867835

L22654

gamma-2a immunoglobulin heavy chain(IgG-2a)

−1.709121

L27487

calcitonin receptor-like(Calcrl)

−1.970351

M11794

No data

−1.536746

M15202

No data

−1.947036

M15327

alcohol dehydrogenase 1 (class I)(Adh1)

−2.079242

M15481

insulin-like growth factor 1(Igf1)

−2.298139

M16409

cholinergic receptor, muscarinic 4(Chrm4)

−1.743017

M18841

No data

−1.998377

M29295

small nuclear ribonucleoprotein polypeptides B and B1(Snrpb)

−1.675114

M30692

No data

−2.027642

M31322

amyloid beta precursor like protein 2(Aplp2)

−1.814887

M57705

thyroid peroxidase(Tpo)

−1.513088

M61142

thimet oligopeptidase 1(Thop1)

−1.696997

M63837

platelet derived growth factor receptor alpha(Pdgfra)

−1.822324

M64381

olfactory receptor 1082(Olr1082)

−1.761637

M76733

glutathione peroxidase 6(Gpx6)

−1.971279

M83143

ST6 beta-galactoside alpha-2,6-sialyltransferase 1(St6gal1)

−1.602127

M83209

BPI fold containing family A, member 2(Bpifa2)

−2.386439

M83210

BPI fold containing family A, member 2F(Bpifa2f)

−1.615422

M83745

proprotein convertase subtilisin/kexin type 1(Pcsk1)

−1.961893

M94043

RAB38, member RAS oncogene family(Rab38)

−1.660598

NM_012490

acrosin(Acr)

−1.761651

NM_012502

androgen receptor(Ar)

−2.367953

NM_012542

cytochrome P450, family 2, subfamily a, polypeptide 3(Cyp2a3)

−1.563632

NM_012589

interleukin 6(Il6)

−2.279895

NM_012595

lactate dehydrogenase B(Ldhb)

−1.56024

NM_012621

6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1(Pfkfb1)

−2.130949

NM_012635

protease, serine 1(Prss1)

−1.938556

NM_012657

serine (or cysteine) proteinase inhibitor, clade A, member 3C(Serpina3c)

−1.73983

NM_012679

No data

−1.660105

NM_012681

transthyretin(Ttr)

−1.632171

NM_012682

uncoupling protein 1(Ucp1)

−1.956669

NM_012703

thyroid hormone responsive(Thrsp)

−2.132157

NM_012706

gastrin releasing peptide receptor(Grpr)

−2.32707

NM_012740

tyrosine hydroxylase(Th)

−1.687967

NM_012777

apolipoprotein D(Apod)

−2.293886

NM_012805

retinoid X receptor alpha(Rxra)

−1.788029

NM_012825

aquaporin 4(Aqp4)

−1.738027

NM_012826

alpha-2-glycoprotein 1, zinc-binding(Azgp1)

−1.917567

NM_012841

DCC netrin 1 receptor(Dcc)

−2.060894

NM_012843

epithelial membrane protein 1(Emp1)

−1.524748

NM_012922

caspase 3(Casp3)

−1.730399

NM_012940

cytochrome P450, family 1, subfamily b, polypeptide 1(Cyp1b1)

−1.825438

NM_012949

enolase 3(Eno3)

−2.250452

NM_012951

fibroblast growth factor 10(Fgf10)

−1.581501

NM_012967

intercellular adhesion molecule 1(Icam1)

−1.527629

NM_012971

potassium voltage-gated channel subfamily A member 4(Kcna4)

−2.126831

NM_013023

S-antigen visual arrestin(Sag)

−1.921779

NM_013054

No data

−1.571264

NM_013095

SMAD family member 3(Smad3)

−1.508985

NM_013159

insulin degrading enzyme(Ide)

−1.663445

NM_013161

pancreatic lipase(Pnlip)

−2.292426

NM_013167

uncoupling protein 3(Ucp3)

−2.046956

NM_013168

hydroxymethylbilane synthase(Hmbs)

−4.18491

NM_013192

potassium voltage-gated channel subfamily J member 6(Kcnj6)

−1.544981

NM_016998

carboxypeptidase A1(Cpa1)

−1.72664

NM_017006

glucose-6-phosphate dehydrogenase(G6pd)

−2.105296

NM_017011

glutamate receptor, metabotropic 1(Grm1)

−1.945417

NM_017014

glutathione S-transferase mu 1(Gstm1)

−2.433956

NM_017019

interleukin 1 alpha(Il1a)

−1.572188

NM_017069

gamma-aminobutyric acid type A receptor alpha3 subunit(Gabra3)

−3.176886

NM_017075

acetyl-CoA acetyltransferase 1(Acat1)

−1.693916

NM_017084

glycine N-methyltransferase(Gnmt)

−1.587023

NM_017085

cytochrome P450, family 19, subfamily a, polypeptide 1(Cyp19a1)

−3.202593

NM_017093

AKT serine/threonine kinase 2(Akt2)

−1.708931

NM_017101

peptidylprolyl isomerase A (cyclophilin A)(Ppia)

−1.962416

NM_017106

chloride voltage-gated channel 5(Clcn5)

−2.303484

NM_017120

casein beta(Csn2)

−1.753558

NM_017156

cytochrome P450, family 2, subfamily b, polypeptide 12(Cyp2b12)

−1.675282

NM_017158

cytochrome P450, family 2, subfamily c, polypeptide 7(Cyp2c7)

−1.9999

NM_017177

choline kinase beta(Chkb)

−1.598296

NM_017179

UNC homeobox(Uncx)

−1.985105

NM_017190

myelin-associated glycoprotein(Mag)

−1.957495

NM_017197

CUGBP, Elav-like family member 2(Celf2)

−2.358172

NM_017228

atrophin 1(Atn1)

−3.12621

NM_017265

hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 6(Hsd3b6)

−1.512438

NM_017285

proteasome subunit beta 3(Psmb3)

−2.192897

NM_017291

gamma-aminobutyric acid type A receptor rho 1 subunit(Gabrr1)

−3.620853

NM_017292

gamma-aminobutyric acid type A receptor rho 2 subunit(Gabrr2)

−1.576548

NM_017326

calmodulin 2(Calm2)

−2.141575

NM_017337

phosphodiesterase 3A(Pde3a)

−1.72263

NM_017339

ISL LIM homeobox 1(Isl1)

−2.983281

NM_017343

myosin light chain 12B(Myl12b)

−1.748003

NM_019182

ring finger protein 4(Rnf4)

−1.852677

NM_019190

CD46 molecule(Cd46)

−1.945158

NM_019211

RAS guanyl releasing protein 1(Rasgrp1)

−1.760087

NM_019241

gap junction protein, beta 5(Gjb5)

−1.748274

NM_019248

neurotrophic receptor tyrosine kinase 3(Ntrk3)

−1.880549

NM_019255

calcium voltage-gated channel auxiliary subunit gamma 1(Cacng1)

−1.569839

NM_019261

killer cell lectin-like receptor subfamily C, member 2(Klrc2)

−2.129231

NM_019270

potassium voltage-gated channel subfamily A member 3(Kcna3)

−2.943964

NM_019278

regulated endocrine-specific protein 18(Resp18)

−2.015828

NM_019285

adenylate cyclase 4(Adcy4)

−1.51557

NM_019299

clathrin heavy chain(Cltc)

−1.670579

NM_019348

somatostatin receptor 2(Sstr2)

−1.921952

NM_019354

uncoupling protein 2(Ucp2)

−2.271891

NM_019363

aldehyde oxidase 1(Aox1)

−1.50887

NM_019620

zinc finger protein 386 (Kruppel-like)(Zfp386)

−2.6169

NM_019621

discs large MAGUK scaffold protein 4(Dlg4)

−1.768061

NM_019907

CXXC repeat containing interactor of PDZ3 domain(Cript)

−1.965978

NM_020074

serglycin(Srgn)

−1.792037

NM_020076

3-hydroxyanthranilate 3,4-dioxygenase(Haao)

−1.647168

NM_020096

interferon-induced protein with tetratricopeptide repeats 1(Ifit1)

−1.569029

NM_020301

ADAM metallopeptidase domain 7(Adam7)

−1.648235

NM_020542

C-C motif chemokine receptor 1(Ccr1)

−1.713195

NM_021580

prolactin family 8, subfamily a, member 4(Prl8a4)

−2.141944

NM_021659

synaptotagmin 7(Syt7)

−1.795637

NM_021672

growth differentiation factor 9(Gdf9)

−1.566303

NM_021676

SH3 and multiple ankyrin repeat domains 3(Shank3)

−2.237337

NM_021703

A-kinase anchoring protein 14(Akap14)

−2.557232

NM_021742

nuclear receptor subfamily 5, group A, member 2(Nr5a2)

−1.603742

NM_021769

sulfotransferase family 1D, member 1(Sult1d1)

−1.883171

NM_022178

myosin VA(Myo5a)

−2.420753

NM_022196

leukemia inhibitory factor(Lif)

−1.875411

NM_022202

glutamate metabotropic receptor 8(Grm8)

−1.511956

NM_022204

exocyst complex component 5(Exoc5)

−1.572194

NM_022214

C-X-C motif chemokine ligand 6(Cxcl6)

−2.525867

NM_022241

prostaglandin D2 receptor(Ptgdrl)

−1.557255

NM_022261

B-box and SPRY domain containing(Bspry)

−1.56046

NM_022278

glutaredoxin(Glrx)

−2.208115

NM_022283

No data

−2.543935

NM_022386

MAF bZIP transcription factor G(Mafg)

−2.383068

NM_022388

FXYD domain-containing ion transport regulator 4(Fxyd4)

−2.897865

NM_022394

scaffold attachment factor B(Safb)

−2.659302

NM_022502

palmitoyl-protein thioesterase 1(Ppt1)

−1.90058

NM_022503

cytochrome c oxidase subunit VIIa polypeptide 2(Cox7a2)

−1.523241

NM_022504

ribosomal protein L36(Rpl36)

−1.906632

NM_022506

ribosomal protein L31(Rpl31)

−2.087805

NM_022530

prolactin family 7, subfamily a, member 3(Prl7a3)

−1.576727

NM_022595

PDGFA associated protein 1(Pdap1)

−2.240738

NM_022597

cathepsin B(Ctsb)

−2.37573

NM_022612

BCL2 like 11(Bcl2l11)

−1.597404

NM_022634

leukocyte specific transcript 1(Lst1)

−1.756651

NM_022694

staphylococcal nuclease and tudor domain containing 1(Snd1)

−2.119255

NM_022711

steroid 5 alpha-reductase 2(Srd5a2)

−1.557239

NM_022797

glutamate ionotropic receptor NMDA type subunit 2D(Grin2d)

−2.63892

NM_022863

iron responsive element binding protein 2(Ireb2)

−1.923661

NM_022867

microtubule-associated protein 1 light chain 3 beta(Map1lc3b)

−1.780024

NM_022949

ribosomal protein L14(Rpl14)

−1.533009

NM_023095

mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase(Mgat5)

−2.000325

NM_023100

neuromedin U receptor 1(Nmur1)

−1.627031

NM_023974

synaptoporin(Synpr)

−1.803122

NM_023998

taste receptor, type 2, member 13(Tas2r13)

−1.675877

NM_024156

annexin A6(Anxa6)

−1.687137

NM_024346

stathmin 3(Stmn3)

−1.575717

NM_024360

hes family bHLH transcription factor 1(Hes1)

−2.146919

NM_024385

hematopoietically expressed homeobox(Hhex)

−1.692521

NM_024388

nuclear receptor subfamily 4, group A, member 1(Nr4a1)

−2.520533

NM_024397

abl-interactor 1(Abi1)

−1.624808

NM_024404

heterogeneous nuclear ribonucleoprotein D(Hnrnpd)

−3.042042

NM_024483

adrenoceptor alpha 1D(Adra1d)

−1.736564

NM_024484

5′-aminolevulinate synthase 1(Alas1)

−1.714727

NM_030857

LYN proto-oncogene, Src family tyrosine kinase(Lyn)

−2.18526

NM_031008

adaptor-related protein complex 2, alpha 2 subunit(Ap2a2)

−1.552738

NM_031055

matrix metallopeptidase 9(Mmp9)

−2.852522

NM_031057

aldehyde dehydrogenase 6 family, member A1(Aldh6a1)

−1.519431

NM_031088

prostaglandin E receptor 2(Ptger2)

−2.221709

NM_031127

sulfite oxidase(Suox)

−2.397507

NM_031236

fucosyltransferase 1(Fut1)

−1.985466

NM_031327

cysteine-rich, angiogenic inducer, 61(Cyr61)

−1.638485

NM_031346

polypyrimidine tract binding protein 3(Ptbp3)

−1.590357

NM_031531

serine (or cysteine) peptidase inhibitor, clade A, member 3N(Serpina3n)

−2.119708

NM_031549

transgelin(Tagln)

−2.37869

NM_031563

Y box binding protein 1(Ybx1)

−1.584841

NM_031590

WNT1 inducible signaling pathway protein 2(Wisp2)

−1.877269

NM_031678

period circadian clock 2(Per2)

−1.587107

NM_031706

ribosomal protein S8(Rps8)

−2.051886

NM_031719

chloride nucleotide-sensitive channel 1A(Clns1a)

−1.549741

NM_031720

deiodinase, iodothyronine, type II(Dio2)

−1.958028

NM_031786

tripartite motif-containing 3(Trim3)

−1.668096

NM_031792

sperm associated antigen 4(Spag4)

−1.634627

NM_031800

death effector domain-containing(Dedd)

−1.641957

NM_031808

calpain 6(Capn6)

−1.820196

NM_031810

defensin beta 1(Defb1)

−2.054222

NM_031828

potassium calcium-activated channel subfamily M alpha 1(Kcnma1)

−1.606975

NM_032056

transporter 2, ATP binding cassette subfamily B member(Tap2)

−2.753854

NM_032062

kalirin, RhoGEF kinase(Kalrn)

−1.810885

NM_033021

SEC31 homolog A, COPII coat complex component(Sec31a)

−1.750599

NM_033095

crystallin, gamma D(Crygd)

−1.569465

NM_053649

kringle containing transmembrane protein 1(Kremen1)

−1.821446

NM_053674

phytanoyl-CoA 2-hydroxylase(Phyh)

−1.905711

NM_053701

calcium voltage-gated channel subunit alpha1 F(Cacna1f)

−1.62128

NM_080689

dynamin 1(Dnm1)

−1.617324

NM_080783

UDP-galactose-4-epimerase(Gale)

−2.373817

NM_130405

KH RNA binding domain containing, signal transduction associated 1(Khdrbs1)

−1.779596

NM_131914

caveolin 2(Cav2)

−1.636241

NM_133403

E1A binding protein p300(Ep300)

−2.567324

NM_133594

small ubiquitin-like modifier 2(Sumo2)

−1.569797

NM_134375

NLR family, pyrin domain containing 6(Nlrp6)

−2.192127

NM_134387

dicarbonyl and L-xylulose reductase(Dcxr)

−2.210838

NM_134432

angiotensinogen(Agt)

−1.737263

NM_134457

siah E3 ubiquitin protein ligase 2(Siah2)

−1.625673

NM_138851

prokineticin 1(Prok1)

−1.918202

NM_138890

EH-domain containing 3(Ehd3)

−1.507669

NM_138976

mitofusin 1(Mfn1)

−1.671108

NM_139082

BMP and activin membrane-bound inhibitor(Bambi)

−2.450906

NM_139097

sodium voltage-gated channel beta subunit 3(Scn3b)

−3.059727

NM_139258

Bcl2 modifying factor(Bmf)

−2.168055

NM_139336

UDP-glucuronate decarboxylase 1(Uxs1)

−1.54412

NM_145673

MAF bZIP transcription factor K(Mafk)

−1.536959

NM_147137

cystatin SC(LOC257643)

−3.032693

NM_152849

homeobox and leucine zipper encoding(Homez)

−1.725448

S75437

No data

−1.965821

U03407

proline rich, lacrimal 1(Prol1)

−2.285635

U03417

olfactomedin 1(Olfm1)

−1.797439

U03630

store-operated calcium entry-associated regulatory factor(Saraf)

−2.016451

U20286

torsin 1A interacting protein 1(Tor1aip1)

−1.727547

U21954

Eph receptor A7(Epha7)

−1.630146

U22663

No data

−1.993711

U24489

tenascin XA, pseudogene 1(Tnxa-ps1)

−2.172308

U28356

protein tyrosine phosphatase, non-receptor type 7(Ptpn7)

−2.374227

U35371

contactin 4(Cntn4)

−1.667741

U40652

protein tyrosine phosphatase, receptor type, N(Ptprn)

−1.867797

U41663

neuroligin 3(Nlgn3)

−1.591787

U41803

mitofusin 2(Mfn2)

−1.574964

U41853

hypoxia up-regulated 1(Hyou1)

−1.657766

U44129

lectin, mannose-binding, 1(Lman1)

−2.451062

U49694

acyl-CoA thioesterase 7(Acot7)

−1.924287

U50948

No data

−1.881066

U53420

No data

−4.016245

U56241

MAF bZIP transcription factor B(Mafb)

−2.421294

U56936

killer cell lectin-like receptor subfamily B member 1B(Klrb1b)

−1.830188

U57362

collagen type XII alpha 1 chain(Col12a1)

−2.0687

U62316

solute carrier family 16 member 7(Slc16a7)

−2.847701

U69702

activin A receptor type 1C(Acvr1c)

−1.705311

U76206

purinergic receptor P2Y14(P2ry14)

−2.320753

U78304

cartilage acidic protein 1(Crtac1)

−1.778874

U81037

neuronal cell adhesion molecule(Nrcam)

−1.502983

U92010

similar to RIKEN cDNA D230025D16Rik(RGD621098)

−1.975117

V01222

albumin(Alb)

−2.265804

X01153

No data

−1.843423

X05034

No data

−1.718179

X13309

WAP four-disulfide core domain 18(Wfdc18)

−2.535182

X53003

acetyl-CoA carboxylase alpha(Acaca)

−1.756607

X54549

transcription factor 3(Tcf3)

−2.43995

X56328

No data

−2.636174

X60822

methionine adenosyltransferase 1A(Mat1a)

−1.586548

X64411

ubiquitin protein ligase E3 component n-recognin 5(Ubr5)

−2.174631

X68101

dedicator of cytokinesis 9(Dock9)

−4.49773

X71463

No data

−1.940264

X73579

Fc fragment of IgE receptor II(Fcer2)

−1.640805

X74815

myosin IE(Myo1e)

−1.973621

X78167

ribosomal protein L15(Rpl15)

−2.28316

X78604

ADP-ribosylation factor like GTPase 5A(Arl5a)

−1.523338

X84004

dual specificity phosphatase 1(Dusp1)

−2.325959

Y12178

ceruloplasmin(Cp)

−1.709408

Y17319

No data

−1.766901

Y17325

NSA2 ribosome biogenesis homolog(Nsa2)

−1.702431

Y17328

crystallin, mu(Crym)

−1.788589

![Effects of exercise on tarsal bone histological parameters in adjuvant-induced arthritis rats. (**A**) Representative images of histological findings in the tarsal joints of the study groups at the end of the exercise intervention using H&E staining. (**B**) Joint involvement was scored by the semi-quantitative scale (showed in E) to describe inflammatory changes and structural remodeling in the tarsal joints (7 rats per group). The t-student test was used to compare histological measurements between groups. \* *p* \< 0.01. (**C**) Exercised rats on a treadmill. (**D**) Representative images of clinical changes on hind paws of adjuvant-induced arthritis (AIA) rats exercised (left) and non-exercised (right). (**E**) Representative images of the inflammation and structural joint damage scores in the tarsal joints of AIA rats. The 0 (normal) score was established in healthy rats, where the bone (bo), cartilage (ca) and synovium (sy) did not show alterations. The arthritis scores 1 (mild), 2 (moderate), and 3 (severe) were based on the inflammatory changes: the presence of synovial hyperplasia (sh) and pannus (pa) and structural remodeling: cartilage damage (cd) and bone erosion (be). The images were acquired with a 10× and 40× amplification. AIA: adjuvant-induced arthritis.](cells-08-01493-g001){#cells-08-01493-f001}

![The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of differentially expressed genes in the DAVID database. The 719 differentially expressed genes by exercise were uploaded into the DAVID database for enrichment analysis. The top 10 GO analysis results of these dysregulated genes were displayed in the bar chart: (**A**) KEGG pathway, (**B**) cellular component, (**C**) biological process and (**D**) molecular function. The bars indicated the -Log10 (*p* value) of each GO and KEGG term. The number of genes involved in each term is shown on the right side of each bar.](cells-08-01493-g002){#cells-08-01493-f002}

![The protein-protein interaction network construction of the cluster number one obtained with the differentially expressed genes. The lists of the differentially expressed genes (Z-score ≥ 1.5 SD) were analyzed on the STRING and Cytoscape platforms. The primary clusters of sub-networks were obtained using the Molecular Complex Detection (MCODE) complement (cutoff = 0.2). Line thickness indicates the strength of data support; colored nodes indicate query proteins and first shell of interactors; white nodes indicate the second shell of interactors.](cells-08-01493-g003){#cells-08-01493-f003}

![The protein-protein interaction network construction of the cluster number two obtained with the differentially expressed genes. The lists of the differentially expressed genes (Z-score ≥ 1.5 SD) were analyzed on the STRING and Cytoscape platforms. The primary clusters of sub-networks were obtained using the Molecular Complex Detection (MCODE) complement (cutoff = 0.2). Line thickness indicates the strength of data support; colored nodes indicate query proteins and first shell of interactors; white nodes indicate the second shell of interactors.](cells-08-01493-g004){#cells-08-01493-f004}

![The protein-protein interaction network construction of the cluster number three obtained with the differentially expressed genes. The lists of the differentially expressed genes (Z-score ≥ 1.5 SD) were analyzed on the STRING and Cytoscape platforms. The primary clusters of sub-networks were obtained using the Molecular Complex Detection (MCODE) complement (cutoff = 0.2). Line thickness indicates the strength of data support; colored nodes indicate query proteins and first shell of interactors; white nodes indicate the second shell of interactors.](cells-08-01493-g005){#cells-08-01493-f005}
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###### 

Differentially expressed genes by physical exercise associated with pathogenic processes in Rheumatoid Arthritis.

  Description                              Effect on Regulation      Number of Genes                                                                                                                                                                     Genes                                                                                                                           *p*-Value                                                                                          
  ---------------------------------------- ------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- --------------
  ***Biological Process***                 Response to hypoxia       Up                                                                                                                                                                                  12                                                                                                                              Camk2d, Cat, Cdkn1b, Il18, Lepr, Mt3, Nppa, Ptk2b, Rhoa, Tgfbr3, Vegfa, Vhl                        3.1 × 10^−3^
  Down                                     17                        Alas1, Bnip3, Cited2, Ep300, Smad3, Casp3, Hmbs, Hyou1, Igf1, Itga2, Icam1, Il1a, Mmp9, Kcnma1, Th, Ucp2, Ucp3                                                                      7.5 × 10^−6^                                                                                                                                                                                                                       
  Oxidation-reduction process              Up                        19                                                                                                                                                                                  Akr1a1, Aifm1, Cbr1, Cyp2d2, Cyp2t1, Cyp27b1, Cyp4f6, Cyp51, Degs1, Gpx1, Hao2, Ido1, Kif1b, Me1, Oxr1, Prdx2, Pah, Txn1, Tpo   1.2 × 10^−2^                                                                                       
  Down                                     26                        Haao, Hibadh, Ndufa12, Aldh6a1, Aox1, Cp, Crym, Cyp19a1, Cyp1b1, Cyp2a3, Cyp2b12, Cyp2p2c7, Cyp2d3, Dio2, Dcxr, G6pd, Glrx, Gpx6, Hsd3b6, Hadhb, Ldhb, Scd, Srd5a2, Suox, Tpo, Th   4.9 × 10^−5^                                                                                                                                                                                                                       
  Hydrogen peroxide catabolic process      Up                        4                                                                                                                                                                                   Cat, Gpx1, Prdx2, Tpo                                                                                                           2.5 × 10^−3^                                                                                       
  Response to oxidative stress             Up                        8                                                                                                                                                                                   Akt1, Cat, Gpx1, Mt3, Map2k1, Oxr1, Prdx2, Tpo                                                                                  7.4 × 10^−3^                                                                                       
  Cellular response to oxidative stress    Up                        5                                                                                                                                                                                   Ggt1, Mt3, Nfe2l2, Prdx2, Txn1                                                                                                  3.2 × 10^−2^                                                                                       
  Cellular response to hydrogen peroxide   Up                        5                                                                                                                                                                                   Anxa1, Aifm1, Il18, Nfe2l2, Ppp5c                                                                                               3.5 × 10^−2^                                                                                       
  Response to reactive oxygen species      Up                        3                                                                                                                                                                                   Cat, Gpx1, Ptk2b                                                                                                                4.1 × 10^−2^                                                                                       
  Inflammatory response                    Up                        12                                                                                                                                                                                  Akt1, Ccl4, Anxa1, Cxcl3, Csf1, Cyp4f6, Crlf2, Hmgb1, Ido1, Il18, Mep1b, Nfe2l2                                                 6.3 × 10^−3^                                                                                       
  ***KEGG signaling pathway***             HIF-1 signaling pathway   Up                                                                                                                                                                                  14                                                                                                                              Akt1, Akt3, Camk2a, Camk2d, Cdkn1b, Hk1, Ifngr1, Map2k1, Nppa, Pik3cb, Pik3r1, Tceb2, Vegfa, Vhl   2.5 × 10^−7^
  VEGF signaling pathway                   Up                        8                                                                                                                                                                                   Akt1, Akt3, Map2k1, Pik3cb, Pik3r1, Ppp3cb, Ppp3r2, Vegfa                                                                       2.5 × 10^−4^                                                                                       
  Rheumatoid Arthritis                     Up                        6                                                                                                                                                                                   Atp6v0a1, Atp6v0e1, Cd80, Csf1, Il18, Vegfa                                                                                     4.2 × 10^−2^                                                                                       
  T cell receptor signaling pathway        Up                        10                                                                                                                                                                                  Akt1, Akt3, Dlg1, Lcp2, Map2k1, Pik3cb, Pik3r1, Ppp3cb, Ppp3r2, Rhoa                                                            4.5 × 10^−4^                                                                                       
  B cell receptor signaling pathway        Up                        7                                                                                                                                                                                   Akt1, Akt3, Map2k1, Pik3cb, Pik3r1, Ppp3cb, Ppp3r2                                                                              3.3 × 10^−3^                                                                                       
  Chemokine signaling pathway              Up                        12                                                                                                                                                                                  Akt1, Akt3, Ccl4, Gng8, Adcy5, Arrb1, Cxcl3, Map2k1, Pik3cb, Pik3r1, Ptk2b, Rhoa                                                1.3 × 10^−3^                                                                                       
  PI3K-Akt signaling pathway               Up                        17                                                                                                                                                                                  Akt1, Akt3, Faslg, Gng8, Csf1, Cdkn1b, Fgd17, Fgf19, Il3ra, Lpar3, Map2k1, Pik3cb, Pik3r1, Ppp2r2c, Vegfa, Ywhae, Ywhag         2.2 × 10^−3^                                                                                       
  Jak-STAT signaling pathway               Up                        10                                                                                                                                                                                  Akt1, Akt3, Cish, Crlf2, Ifngr1, Il3ra, Lepr, Pik3cb, Pik3r1, Thpo                                                              2.2 × 10^−3^                                                                                       
  TNF signaling pathway                    Up                        7                                                                                                                                                                                   Akt1, Akt3, Cxcl3, Csf1, Map2k1, Pik3cb, Pik3rc1                                                                                2.8 × 10^−2^                                                                                       
  Toll-like receptor signaling pathway     Up                        7                                                                                                                                                                                   Akt1, Akt3, Ccl4, Cd80, Map2k1, Pik3cb, Pik3r1                                                                                  1.7 × 10^−2^                                                                                       
  Wnt signaling pathway                    Up                        10                                                                                                                                                                                  Wif1, Camk2a, Camk2d, Csnk2a1, Csnk2b, Ctnnb1, Fzd4, Ppp3cb, Ppp3r2, Rhoa                                                       3.0 × 10^−3^                                                                                       
  Osteoclast differentiation               Up                        13                                                                                                                                                                                  Akt1, Akt3, Fcgr2a, Csfr1, Ifngr1,Lilrb3l, Lcp2, Mapk2k1, Pik3cb, Pik3r1, Ppp3cb, Ppp3r1, Ppp3r2                                8.6 × 10^−5^                                                                                       
